139886-28-5

Basic information

• Product Name: (E)-N-hydroxy-1-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methanimine hydrochloride (1:1)
• CAS NO: 139886-28-5
• Molecular Formula: C₇H₁₃ClN₂O
• Molecular Weight: 176.6439
• Mol File: 139886-28-5.mol

Chemical Properties

• Boiling Point: 248.7°C at 760 mmHg
• Flash Point: 104.2°C
• Vapor Pressure: 0.00385mmHg at 25°C
• CAS DataBase Reference: (E)-N-hydroxy-1-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methanimine hydrochloride (1:1)(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-N-hydroxy-1-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methanimine hydrochloride (1:1)(139886-28-5)
• EPA Substance Registry System: (E)-N-hydroxy-1-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methanimine hydrochloride (1:1)(139886-28-5)

Safety Data

• Hazardous Substances Data: 139886-28-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
HPPH is used as a potential therapeutic agent for cancer treatment, specifically for targeting and destroying tumor cells. Its unique properties make it a promising candidate for the development of novel cancer therapies.
Used in Photodynamic Therapy:
In the field of photodynamic therapy, HPPH is used as a photosensitizer to kill cancer cells. This treatment method involves the use of light and a photosensitizer, which in this case is HPPH, to trigger a reaction that leads to the destruction of cancerous cells.
Used in Oncology Research:
HPPH is utilized as a subject of study in oncology research, where its structure and properties are investigated for potential applications in the development of new cancer treatments and therapies.

Upstream product

• 114485-45-9 1-methyl-1,2,5,6-tetrahydropyridine-3-carboxaldehyde hydrochloride 

Relevant articles and documents

1-Alkyl-1,2,5,6-tetrahydropyridine-3-carboxaldehyde-O-alkyl-oximes: A new class of potent orally active muscarinic agonists related to arecoline

On the basis of the knowledge acquired for basic studies of several known arecoline derivatives about the structural requirements for potent agonistic activity and oral efficacy, a series of 1-alkyl-1,2,5,6-tetrahydropyridine-3-carboxaldehyde-O-alkyl-oximes was synthesized and biologically evaluated in a battery of in vitro and in vivo assays. The most interesting molecules to emerge from the primary screening, 1,2,5,6-tetrahydropyridine-3-carboxaldehyde-O-methyloxime hydrochloride (11, RU 35963), 1-methyl-1,2,5,6-tetrahydropyridine-3-carboxyaldehyde-O-methyloxime hydrochloride (12, RU 35926), and 1,2,5,6-tetrahydropyridine-3-carboxyaldehyde-O-propargyloxime hydrochloride (30, RU 47029) and 1-methyl-1,2,5,6-tetrahydropyridine-3-carboxaldehyde-O-propargyloxime hydrochloride (33, RU 35986), were evaluated more extensively, and their cholinomimetic profile was compared with that of the parent molecule, arecoline. The pharmacological results after oral administration to mice and rats revealed that their efficacy is 2-3 orders of magnitude higher than that of arecoline, and, in addition, they show a longer duration of action. The 4 aldoximes showed anti-amnesic properties in many respects superior to those of arecoline. Their anti-amnesic doses were 2 orders of magnitude lower than those inducing obvious cholinergic symptoms, and 3-5 orders of magnitude lower than the lethal doses. These new compounds can be regarded as potential candidates for clinical studies in AD (Alzheimer's disease) patients.